Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.37 |
| ▸ | DRD2 | P14416 | 5/20 | 0.34 |
| ▸ | DRD3 | P35462 | 5/20 | 0.34 |
| ▸ | DRD1 | P21728 | 3/20 | 0.34 |
| ▸ | DRD4 | P21917 | 3/20 | 0.34 |
| ▸ | DRD5 | P21918 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063484 | 1.00 | KIF11 (0.37) | KIF11DRD2DRD3DRD1DRD4 | |
| SCHEMBL28766813 | 0.87 | DRD2 (0.35) | KIF11DRD2DRD3DRD1DRD4 | |
| SCHEMBL4032657 | 0.86 | NR1H2 (0.42) | KIF11 | |
| SCHEMBL4032654 | 0.86 | NR1H2 (0.42) | KIF11 | |
| SCHEMBL4977372 | 0.82 | RBP4 (0.34) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL6916082 | 0.81 | BCHE (0.36) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL13987854 | 0.79 | DRD2 (0.34) | KIF11DRD2DRD3DRD1DRD4 | |
| SCHEMBL23452363 | 0.78 | DRD2 (0.30) | DRD2DRD3 | |
| SCHEMBL21199459 | 0.78 | DRD2 (0.30) | DRD2DRD3 | |
| SCHEMBL21199457 | 0.78 | DRD2 (0.30) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664026-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2009-01-21 | — | — | EP | disclosed |
| US-7465746-B2 | Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP | MERCK & CO., INC. (US) | 2008-12-16 | — | — | US | disclosed |
| EP-1636182-A4 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20060234984-A1 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | MERCK & CO., INC. | 2006-10-19 | — | — | US | disclosed |
| EP-1664026-A1 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1636182-A2 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005019206-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005019205-A1 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043357-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-02-24 | — | — | US | disclosed |
| US-20050038074-A1 | Mitotic kinesin inhibitors | COLEMAN PAUL J (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2004111193-A2 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234984-A1 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | KIF5B, KIF2C, KIF5C | KIF11 10/4885DRD2 4533/4885DRD3 4561/4885 |
| US-20050043357-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | KIF11 8/4885DRD2 4616/4885DRD3 4482/4885 |
| US-20050038074-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | KIF11 8/4885DRD2 4616/4885DRD3 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.